FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today announced the launch of its cutting-edge Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare, and redefine the growing field of epigenetic research.

FOXO’s Bioinformatics Services offers a comprehensive platform of advanced data solutions tailored to meet the specific needs of clients in academia, healthcare, and pharmaceutical research. Through its innovative suite of bioinformatic tools, FOXO will enable its clients to increase the speed and accuracy with which they process, analyze, and interpret data sets, accelerate discoveries, and advance their understanding of complex diseases.

“The launch of FOXO’s Bioinformatics Services marks a significant milestone for FOXO Technologies and the field of epigenetic research,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “Epigenetics plays a key role in gene regulation and the interplay between lifestyle and environmental factors on biological systems. However, harnessing the full potential of epigenetic data has long been hindered by the challenges of data processing, analysis, and interpretation. With the introduction of our Bioinformatics Services, we aim to eliminate these barriers and empower researchers, clinicians, and other organizations to accelerate their research.”

Any researcher or research group that seeks to leverage DNA methylation microarrays can benefit from FOXO’s Bioinformatics Services. These services include ingesting and processing raw DNA methylation microarray data, performing sample- and probe-level quality control, and securely delivering publication-ready figures and results. FOXO’s expert team also offers the addition of advanced bioinformatic analyses including epigenome wide association studies (EWAS), and even AI-driven epigenetic biomarker development. These services can be applied to Illumina’s existing human and mouse DNA Methylation arrays, which cover over 935,000 and 285,000 CpG sites respectively. By leveraging state-of-the-art algorithms and world-class experts, the company’s bioinformatics platform can rapidly deliver accurate and high-quality data tailored to the needs of each client.

“Epigenetics is a nuanced science. Through years of experience, our team has developed niche expertise in bioinformatics with respect to epigenetics, specifically. Researchers who wish to incorporate epigenetic data into their studies can save valuable time and effort through our services offering,” says Brian Chen, Chief Science Officer.

As a leader in the field, FOXO remains committed to advancing epigenetic research and catalyzing breakthroughs in health and longevity. With Bioinformatic Services, FOXO is also opening the door to new research collaborations with industry and academic leaders.

For more information about FOXO and their bioinformatic services, please visit www.foxotechnologies.com.

About FOXO Technologies Inc. (“FOXO”):

FOXO is at the forefront of commercializing epigenetic biomarker technology. Their mission is to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity outcomes for individuals and organizations alike.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by the management team of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,” “plan,” “project,” “possible,” “potential,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk of changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; (ii) the ability to implement FOXO’s business plans, forecasts, and other expectations; (iii) the ability to obtain financing if needed; (iv) the ability to maintain its NYSE American listing; (v) the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; (vi) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; (vii) the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and (viii) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO’s prospective customers operate. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Relations
Matthew Hausch, Cody Slach
Gateway Investor Relations
(949) 574-3860
FOXO@gatewayir.com